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Abstract
Background: The influenza A virus replicates in the nucleus of its host cell. Thus, entry of the
influenza genome into the cell nucleus is necessary for establishing infection. The genome of the
influenza A virus consists of eight single-stranded, negative-sense RNA molecules, individually
packed with several copies of the viral nucleoprotein (NP) into ribonucleoprotein particles
(vRNPs). These vRNPs are large, rod-shaped complexes containing a core of NP, around which the
RNA is helically wrapped. The vRNPs are the entities that enter the nucleus, and their nuclear
import must be mediated by nuclear localization sequences (NLSs) exposed on the vRNPs. NP
contains at least two putative NLSs, one at the N-terminus (NLS1) and one in the middle (NLS2)
of the protein. These NP NLSs have been shown to mediate the nuclear import of recombinant
NP molecules. However, it remains to be determined which NLS mediates the nuclear import of
influenza vRNP complexes.
Results: To directly track the nuclear import of the influenza A genome, we developed an
experimental assay based on digitonin-permeabilized cells and fluorescently-labeled vRNPs isolated
from the influenza A virus. We used this assay to determine the contribution of the two proposed
NLSs on NP to the nuclear import of influenza vRNP complexes. Peptides that mimic each of the
two NLSs on NP were used to compete with vRNPs for their nuclear import receptors. In addition,
antibodies against the two NP NLSs were used to block the NLSs on the vRNP complexes, and
thereby inhibit vRNP nuclear import. Both peptide competition and antibody inhibition of either
sequence resulted in decreased nuclear accumulation of vRNPs. The two sequences act
independently of each other, as inhibition of only one of the two NLSs still resulted in significant,
though diminished, nuclear import of vRNPs. Furthermore, when both sequences were blocked,
vRNP nuclear import was almost completely inhibited. Antibody inhibition studies further showed
that NLS1 on NP is the main contributor to the nuclear import of vRNPs.
Conclusion: Our results demonstrate that both NLS1 and NLS2 on NP can mediate the nuclear
uptake of influenza A vRNPs.
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Background
As part of its replication cycle, the genome of the influ-
enza A virus must enter the nucleus of its host cell. The
influenza A virus genome consists of eight single-
stranded, negative-sense viral RNA (vRNA) molecules of
varying sizes that are individually packed and stabilized
by multiple copies of nucleoprotein (NP; ~56 kDa) into
viral ribonucleoprotein (vRNP) complexes. NP forms a
core around which the vRNA is helically wrapped [1].
Approximately 24 nucleotides associate with each NP
[2,3]. Thus, given that each vRNA is about 890–2,341
nucleotides long (reviewed in [4]), each influenza vRNP
has 37–97 copies of NP. The crystal structure of oligo-
meric NP has recently been solved and revealed a possible
RNA-binding groove made up of a large number of basic
residues [5]. In addition to NP, each vRNP also contains a
single copy of a trimeric RNA polymerase complex. In the
virus, these vRNPs are enclosed by the viral envelope, and
are organized into a distinct pattern with seven vRNPs in
a circle surrounding one vRNP at the center [6]. During
cell entry, the influenza virion containing these incoming
vRNP complexes is internalized into an endosomal com-
partment by either clathrin- or caveolae-dependent mech-
anisms [7,8]. The acidic environment of the endosome
then triggers the fusion of the viral envelope with the
endosomal membrane to release the vRNPs into the cyto-
plasm. The vRNPs are then transported in the cytoplasm
by diffusion [9], and gain access to the nuclear import
machinery of the cell (nuclear pore complexes (NPCs)
and soluble nuclear import receptors). After reaching the
NPCs, the vRNPs are then imported into the nucleus in an
energy-dependent manner [9-11]. The nuclear import of
incoming vRNPs allows for subsequent genomic replica-
tion; nuclear transcription and cytoplasmic synthesis of
new viral proteins; nuclear import of newly-synthesized
NP and RNA polymerases; and nuclear assembly and
export of newly-synthesized vRNP complexes (reviewed
in [12-15]).
Two mechanisms for nuclear import exist [16,17]: Passive
diffusion occurs for molecules less than 9 nm in diameter,
or proteins smaller than 40 kDa. Facilitated translocation,
on the other hand, can accommodate molecules up to 39
nm in diameter [18]. This mechanism is highly selective
and requires the energy from GTP hydrolysis by the small
GTPase Ran [19,20]. In addition, facilitated translocation
requires a signal residing on the imported molecule (or
cargo), and soluble cytoplasmic receptors that recognize
the signal and carry the cargo through the NPC. A major
breakthrough in the study of nuclear import has been the
recent identification of several signals and transport recep-
tors mediating different nuclear transport pathways. The
first-identified and best-studied nuclear import signal is
characterized by one (monopartite) or two (bipartite)
short stretches of basic amino acids, called nuclear locali-
zation sequences (NLSs) [21-23], and is now referred to as
the classical NLS or cNLS. The receptor for the cNLS con-
sists of two proteins, importin α and importin β. The cNLS
is recognized by importin α, which acts as an adapter
between the cNLS-bearing protein and importin β, the
subunit which interacts directly with the NPC [24,25]. In
addition, many other NLSs have been now identified
(reviewed in [26]), and they bind different transport
receptors that belong to an increasing family of proteins
related to the importins.
Since influenza vRNPs enter the nucleus through the NPC
via facilitated translocation [10], one or more exposed
NLSs on the vRNPs must be responsible for mediating
their nuclear import. Although all four proteins of influ-
enza vRNPs (NP and the three RNA polymerases) carry
NLSs, NP is believed to be the protein responsible for the
nuclear import of influenza vRNPs. This hypothesis is
based on experimental data that have demonstrated that
NP mediates the nuclear import of in vitro-assembled NP-
RNA complexes [27,28]. NP contains at least two NLSs:
one at the N-terminus of NP (residues 1–13; NLS1)
[29,30], and one in the middle of NP (residues 198–216;
NLS2) [31]. Both sequences function as NLSs when fused
to cytoplasmic proteins [30,31]. However deletion of
both NLS1 and NLS2 still results in nuclear accumulation
of NP, suggesting the presence of a third NLS [32], whose
precise location is yet to be mapped. NLS1 has been stud-
ied in some detail and it is known that it binds to impor-
tin α1 and α5 [30], two of the six human homologues of
importin αs currently identified (α1, α3, α4, α5, α6, α7)
(reviewed in [33,34]). NLS2 is less well characterized, and
was originally proposed to be a classical bipartite NLS.
However, the recently-solved crystal structure of NP sug-
gests that the two clusters of basic amino acids in NLS2 are
too close to be recognized by importin α as a bipartite NLS
[5]. Because mutations of the second cluster of basic
amino acids (positions 213, 214 and 216) of NLS2 are
critical to the nuclear import of recombinant NP [31], it is
possible that this region may act as a monopartite NLS.
The specific importin α homologue that recognizes NLS2
remains to be identified. However, since full length NP
binds to importin α1,  α3, and α5 [35], any of these
homologues may recognize NLS2.
The contribution of NLS1 and NLS2 to the nuclear import
of NP is controversial because they have been shown to
mediate the nuclear import of recombinant NP in some
studies but not in others [27,29,31,32]. Because NP forms
small oligomers in equilibrium with monomers [5,36], it
is unclear whether the NLSs on NP function during the
oligomeric or the monomeric state of NP, and whether
the different tags fused to recombinant NP in those stud-
ies may have interfered with the NLSs, or with the oli-
gomerization of NP and consequent exposure of the NLSs.Virology Journal 2007, 4:49 http://www.virologyj.com/content/4/1/49
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It is also unknown from these studies whether newly-syn-
thesized NP enters the nucleus as oligomers or as mono-
mers.
While the contribution of the NLSs to the nuclear import
of newly-synthesized NP is controversial, even less is
known about the specific NLS(s) that target incoming
influenza virus-derived vRNP complexes to the nucleus. It
has recently been shown that the nuclear import of in
vitro-assembled NP-RNA complexes was mediated by
NLS1 on NP [27]. However these studies used recom-
binant NP with GFP fused to its C-terminus, which may
have interfered with the assembly of NP because accord-
ing to the crystal structure of NP, oligomerization requires
a tail loop close to the C-terminus (residues 402–428) [5].
Thus these in vitro-assembled RNPs may differ structurally
from influenza-assembled vRNP complexes within mam-
malian cells. More recently, a reverse genetics approach,
essentially involving the co-transfection of recombinant
RNA and NP under the control of non-influenza promot-
ers, has also noted an important role of NLS1 in mediat-
ing influenza RNA nuclear import [37]. Compared to in
vitro-assembled RNPs or recombinant RNA and NP, how-
ever, it is possible that naturally-occurring, influenza
virus-derived vRNPs may not actually utilize NLS1, or
may also require NLS2, on NP for proper nuclear import.
In this study, we address these key questions by studying
the nuclear import of vRNP complexes isolated from nat-
urally-occurring influenza A virions.
Results
Purification and biotinylation of influenza vRNP 
complexes
To study the nuclear import of the influenza genome it
was important to first establish a method to purify and
fluorescently label the influenza vRNPs in their native
state. To purify the influenza vRNPs we used the well-
established protocol of Kemler et al. [38], which consists
of disrupting the influenza virions and then separating the
released vRNPs from the other components of the virus by
velocity sedimentation on a glycerol gradient. To mimic as
closely as possible the conditions that influenza vRNPs
undergo during cell infection after being internalized into
endosomes, the vRNPs were purified under acidic condi-
tions (pH 5.5). Fig. 1 represents a typical distribution pro-
file of the proteins in the fractions. As previously shown
[38], this procedure yields fractions containing vRNPs
devoid of M1 and other influenza viral proteins, as judged
by the presence of only the NP protein by Coomassie blue
staining of the gel. Since M1 has been found to inhibit
nuclear import of the vRNP complex [11,39], it was
important to pool fractions containing NP but not M1 (as
indicated in Fig. 1). These fractions, containing the vRNP
complexes, were pooled, concentrated, and used for sub-
sequent fluorescent labeling.
To track the nuclear import of the influenza genome, the
vRNA within the purified vRNP complex was biotinylated
in order to attach a streptavidin fluorophore. For this pur-
pose, we used the 5' End Tag Nucleic Acid Labeling System
(Vector Laboratories), which covalently attached a reac-
tive thiophosphate group to the 5' end of the vRNA within
the vRNP. This allowed for the attachment of biotin-male-
imide (a thiol-specific biotin reagent), and the subsequent
tagging of fluorescein-streptavidin to yield fluorescein-
labeled vRNPs. To verify that the vRNPs were properly
biotinylated, their vRNAs were subjected to Northern
blotting using streptavidin alkaline phosphatase. As
shown in Fig. 2A, the vRNA was successfully biotinylated
and ran near the top of the urea gel. Fig. 2B shows the
same sample, but using the SYBR Safe dye to directly
detect the vRNA on the urea gel. The stained vRNA
(arrows), similar to the Northern blot, ran near the top of
the gel. As the vRNA appeared to be larger than 4,000 bp
and did not run as a smear or as distinct RNA bands, this
indicates that the vRNA was still associated to the NP oli-
gomer as part of the vRNP complex, and not dissociated
from the protein components.
To confirm that biotin was added at one end of the vRNPs,
the biotinylated vRNPs were incubated with streptavidin-
gold, and the gold-tagged vRNP complexes were nega-
tively stained and visualized by transmission electron
microscopy. As illustrated in Fig. 2C, the vRNPs had the
expected rod shape, and one end of the rod was labeled
with an electron-dense gold particle.
Fluorescein-labeled influenza vRNPs are competent for 
nuclear import
The nuclear import of fluorescein-labeled influenza
vRNPs was studied in the well-established nuclear import
assay involving digitonin-permeabilized cells [40]. Digi-
tonin permeabilizes the plasma membrane of cells, but
retains the integrity of the nuclear envelope; digitonin-
permeabilized cells therefore have intact import-compe-
tent nuclei, but are depleted of cytosolic nuclear import
receptors. To ensure that the nuclear import assay was
working properly, a series of controls were performed.
First, a fluorescently-labeled dextran with a size that
exceeds the diffusion limit of the NPC was used to control
for nuclear envelope integrity. As shown in Fig. 3A, the 70
kDa dextran labeled with Texas Red entered the plasma
membrane but was almost totally excluded from the
nucleus (indicated by the presence of fluorescence signal
in the cytoplasm but not in the nucleus). This indicates
that the plasma membrane was permeabilized, while the
integrity of the nuclear envelope was maintained.
To ensure that the digitonin-permeabilized cells sup-
ported nuclear import, we used a positive control import
substrate, the simian virus 40 large T antigen NLS cross-Virology Journal 2007, 4:49 http://www.virologyj.com/content/4/1/49
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linked to BSA (NLS-BSA) and fluorescently labeled it with
Cy3 (Cy3-NLS-BSA). As shown in Fig. 3B, Cy3-NLS-BSA
efficiently accumulated in the nucleus of digitonin-per-
meabilized cells in the presence of exogenous cytosol and
an energy-regenerating system. Quantitation of the fluo-
rescence intensity in the nucleus and cytoplasm revealed
that Cy3-NLS-BSA accumulated in the nucleus at levels
3.5-fold greater than in the cytoplasm (Fig. 3C). In con-
trast, in the absence of exogenous cytosol and an energy-
regenerating system, Cy3-NLS-BSA was found mainly
throughout the cytoplasm, and unable to accumulate
effectively in the nucleus. Although quantitation of the
fluorescence intensity indicated that a small amount of
Cy3-NLS-BSA was in the nucleus in the absence of exoge-
nous cytosol and an energy-regenerating system (Fig. 3C),
this was probably due to residual cytosolic import factors
and energy remaining in the permeabilized cells, which
has been previously reported [24]. In agreement with this
explanation, blocking the NPCs with the monoclonal
antibody 414 prevented nuclear import (data not shown).
Next, we tested whether the fluorescein-labeled influenza
vRNPs (fluorescein-vRNP) were competent for nuclear
import. As illustrated in Fig. 3B, similar to Cy3-NLS-BSA,
fluorescein-vRNP efficiently accumulated in the cell
nucleus under permissive conditions (+cytosol + energy).
As revealed from the quantitation of the fluorescence
intensity (Fig. 3C), the level of nuclear accumulation of
fluorescein-vRNP under permissive and non-permissive
conditions was comparable to that of Cy3-NLS-BSA. Con-
sistent with previous reports, the vRNP complexes were
especially prone to accumulation at the nucleolus [37,41].
Taken together, these results demonstrate that the nuclear
import assay with digitonin-permeabilized cells is func-
tional, and that the fluorescein-labeled vRNPs are compe-
tent for nuclear import.
Peptides mimicking NLS1 or NLS2 on NP inhibited the 
nuclear import of influenza vRNPs
To understand the contributions of the two putative NLSs
on NP to the nuclear import of influenza vRNPs, peptides
that mimic the NP NLS1 or NLS2 were used to compete
with the vRNPs for their nuclear import receptors (the
importin αs). Our hypothesis for these peptide competi-
tion experiments was that if a peptide served as an NLS
that is responsible for the nuclear import of influenza
vRNP, that peptide would bind to its nuclear import
receptor. Thereby, the receptor would be unavailable to
bind to and import the vRNPs into the nucleus. Figure 4A
shows a representative peptide competition experiment
performed with fluorescein-vRNPs in digitonin-permea-
bilized cells. As shown in Fig. 4A, a control peptide con-
sisting of a mutated NLS [42] did not inhibit the nuclear
import of fluorescein-vRNPs. Similarly, quantitation of
the nuclear-to-cytoplasmic fluorescence in conditions
with and without control peptide revealed that the
nuclear accumulation of fluorescein-vRNP was similar in
Fractionation profile of the purification of vRNP complexes from influenza A by glycerol gradient centrifugation Figure 1
Fractionation profile of the purification of vRNP complexes from influenza A by glycerol gradient centrifuga-
tion. Fractions were collected from the top (lane 1) to the bottom (lane 16) of a glycerol gradient and analyzed via reducing 
SDS-PAGE containing 10% polyacrylamide. The gel was stained with Coomassie blue. The arrows indicate the mobility of the 
influenza NP and M1 proteins. The positions of the molecular weight standards (in kDa) are indicated to the left.Virology Journal 2007, 4:49 http://www.virologyj.com/content/4/1/49
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the two samples. In contrast, nuclear accumulation of flu-
orescein-vRNP was reduced in the presence of either the
NLS1 peptide or the NLS2 peptide. Moreover, nuclear
import of fluorescein-vRNP was further reduced when
both NLS1 and NLS2 peptides were included.
Biotinylation of influenza vRNPs Figure 2
Biotinylation of influenza vRNPs. (A) Northern blot of 
biotinylated influenza vRNA in the vRNP complexes. The 
biotinylated vRNPs were subjected through urea gel electro-
phoresis, transferred onto nitrocellulose, and detected by 
blotting with streptavidin alkaline phosphatase. Shown are 
the results of the same blot exposed at two different times. 
As a control, biotin maleimide only was run on the gel. Urea 
gel electrophoresis of the same biotinylated influenza vRNA 
shown in A. (B) The vRNA within the vRNP complex was 
visualized directly by staining the gels with SYBR Safe. The 
arrows denote the positions of the influenza vRNA. Two dif-
ferent concentrations of the vRNA are shown. The positions 
of various sizes of RNA molecular standards (in bp) are 
shown on the left. (C) Electron microscopy visualization of 
specific binding of streptavidin-gold (10-nm diameter) to 
biotinylated influenza vRNPs. Gold particles exclusively asso-
ciated with one end of the vRNPs.
Nuclear import of fluorescein-labeled influenza vRNPs Figure 3
Nuclear import of fluorescein-labeled influenza 
vRNPs. Fluorescein-labeled influenza vRNPs are competent 
for nuclear import. Nuclear import assays were carried out 
in digitonin-treated HeLa cells, and cells were visualized by 
confocal microscopy. Representative images of three inde-
pendent experiments are shown. (A) Control experiment 
with a 70 kDa dextran fluorescently-labeled with Texas Red 
to verify that the plasma membrane, but not the nuclear 
envelope, is permeabilized by digitonin. (B) Cy3-labeled BSA 
carrying a classical NLS (Cy3-NLS-BSA) and fluorescein-
labeled influenza vRNP complexes (fluorescein-vRNP) were 
assayed in the digitonin permeabilized HeLa cells. Nuclear 
import assays were carried out in import buffer alone (- 
energy - cytosol) or in the presence of exogenous cytosol 
and an energy-regenerating system (+ energy + cytosol). (C) 
Bar diagram of the ratio of nuclear-to-cytoplasmic fluores-
cence for the experimental conditions shown in A and B. 
Each bar graph shows the mean value and standard error 
from 100–110 individual cells.Virology Journal 2007, 4:49 http://www.virologyj.com/content/4/1/49
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The results displayed in Fig. 4 are for conditions in which
the NLS1 peptide or NLS2 peptide was included in the
presence of the control peptide added at a 1:1 ratio. (All
conditions contained the same total molarity of peptides,
so the control peptide was added to maintain constant
peptide concentrations when comparing with the NLS1 +
NLS2 double peptide competition condition.) Experi-
ments were also performed with just the NLS1 peptide or
NLS2 peptide in the absence of a control peptide, and a
similar inhibition profile was obtained (results not
shown). In either case, inhibition of either NLS1 or NLS2
alone did not completely inhibit the nuclear import of the
fluorescein-vRNP. This indicates that NLS1 and NLS2 act
independently of each other to promote nuclear import of
the vRNPs since inhibition of only one NLS still resulted
in a certain degree of vRNP nuclear accumulation. Fur-
thermore, this inhibitory effect was additive because when
a combination of NLS1 + NLS2 peptides were added, a sig-
nificantly larger reduction in the nuclear import of the
vRNPs occurred (Fig. 4).
Antibodies against NLS1 or NLS2 of NP inhibited the 
nuclear import of influenza vRNPs
To verify the results of the peptide competition experi-
ments, a second approach consisting of antibody inhibi-
tion was used. For this purpose, antibodies against NLS1
or NLS2 of NP were applied in the nuclear import assay
with digitonin-permeabilized HeLa cells using fluores-
cein-vRNP in the presence of exogenous cytosol and an
energy-regenerating system. Our hypothesis was that
these antibodies would bind to the vRNP complexes and
prevent the association of importinα to the vRNPs,
thereby inhibiting fluorescein-vRNP nuclear import. As a
control antibody, we applied anti-BSA. As shown in Fig. 5,
the anti-BSA control antibody did not affect the nuclear
import of fluorescein-vRNP. However, in the presence of
either the anti-NLS1 or anti-NLS2 antibodies, nuclear
accumulation of fluorescein-vRNP was substantially
decreased. Furthermore, similar to the peptide competi-
tion studies, antibody inhibition of both NLS1 and NLS2
resulted in an even greater decrease in fluorescein-vRNP
nuclear import compared to inhibition with a single anti-
body (Fig. 5). Results shown in Fig. 5 are for experiments
in which the control antibody was included with the anti-
NLS1 antibody or anti-NLS2 antibody to maintain a con-
stant total antibody concentration. However, similar
results were obtained when only the anti-NLS1 antibody
or anti-NLS2 antibody was added without the control
antibody (results not shown).
The antibody inhibition results generally agree with those
of the peptide competition experiments described above
(Fig. 4). However, inhibiting the NLSs with antibodies
seemed to be more effective in inhibiting the nuclear
import of the fluorescein-vRNPs, than competing with
Competition of influenza vRNP nuclear import with peptides  against NP NLSs Figure 4
Competition of influenza vRNP nuclear import with 
peptides against NP NLSs. Peptides carrying the NLSs of 
influenza NP compete for nuclear import of influenza vRNPs. 
(A) Fluorescein-labeled influenza vRNPs were assayed in digi-
tonin-permeabilized HeLa cells in the presence of cytosol, an 
energy-regenerating system, and the absence or presence of 
different peptides. Cells were visualized by confocal micros-
copy, and representative images of three independent exper-
iments are shown. (B) Bar diagram of the ratio of nuclear-to-
cytoplasmic fluorescence for the experimental conditions 
shown in A. Each bar graph shows the mean value and stand-
ard error from 100–110 individual cells.Virology Journal 2007, 4:49 http://www.virologyj.com/content/4/1/49
Page 7 of 12
(page number not for citation purposes)
these sequences. Furthermore, a difference was observed
in the inhibition of NLS1 versus NLS2 with the antibod-
ies, but not with the peptides. The discrepancy between
these antibody results, which showed a difference
between the two NLSs versus the peptide competition
results, occurred probably because the antibodies directly
inhibited nuclear import by blocking the NLSs on the
vRNP, while the peptides indirectly inhibited nuclear
import by competing for the vRNP nuclear import recep-
tors. If so, the antibody inhibition results would indicate
that while both NLS1 and NLS2 of NP may be involved in
mediating the nuclear import of virally-derived vRNP
complexes, the contribution of NLS1 is slightly greater.
Discussion
Using influenza vRNPs purified under acidic conditions,
and thus mimicking physiologically-relevant influenza
infections as closely as possible, we have found that inhi-
bition of either NLS1 or NLS2 on influenza NP signifi-
cantly inhibited the nuclear import of influenza vRNP
complexes. Therefore, both NLS1 and NLS2 on NP are
involved in mediating the nuclear import of incoming
vRNP complexes. These two sequences act independently
of each other, as peptide competition with or antibody
inhibition of only one of these sequences still resulted in
a certain, though less pronounced, degree of nuclear
import of vRNPs. Furthermore, when both NLS1 and
NLS2 were competed with peptides or blocked by anti-
bodies, the nuclear import of the vRNPs was even more
drastically reduced.
Some differences, however, existed in the ability of the
NLS peptides versus the anti-NLS antibodies to inhibit
nuclear import of the vRNPs. These differences were likely
due to the nature of the competition experiments, since
peptide competition with the vRNPs for the cytosolic
nuclear import receptors is less specific than direct inhibi-
tion of the vRNP NLSs with antibodies. The antibody inhi-
bition experiments may hence provide a more accurate
picture of the relative contributions of NLS1 and NLS2 to
influenza vRNP nuclear import. From these results, it
appears that peptides mimicking or antibodies against
these conserved NLS regions on NP may be an effective
means of interrupting a critical stage in the influenza A life
cycle.
Interestingly, performing a sequence alignment (using
Clustal W [43]) of NP from different influenza A strains,
we can observe that each of NLS1 and NLS2 on NP are
highly conserved among influenza A strains. However,
NLS1 and NLS2 do not share much similarity with any
region on NP of influenza B or C, as analyzed from a Clus-
tal W alignment. This is in agreement with previous stud-
ies that have not been able to pinpoint the NLS in NP for
influenza B [44], so it appears that influenza B and C may
Inhibition of influenza vRNP nuclear import with antibodies  against NP NLSs Figure 5
Inhibition of influenza vRNP nuclear import with 
antibodies against NP NLSs. Antibodies against the NLSs 
of influenza NP inhibit the nuclear import of influenza vRNPs. 
(A)Fluorescein-labeled influenza vRNPs were assayed in the 
digitonin-permeabilized HeLa cells in the presence of cytosol, 
an energy-regenerating system, and the absence or presence 
of different antibodies. Cells were visualized by confocal 
microscopy, and representative images of three independent 
experiments are shown. (B) Bar diagram of the ratio of 
nuclear-to-cytoplasmic fluorescence for the experimental 
conditions shown in A. Each bar graph shows the mean value 
and standard error from 100–110 individual cells.Virology Journal 2007, 4:49 http://www.virologyj.com/content/4/1/49
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utilize NLSs that are different from those of influenza A.
With respect to NLS1, the only residue conserved among
influenza A, B, and C is a conserved arginine at position 8
of the influenza A NP, which agrees with previous studies
indicating that that residue is one of the most important
residues involved in mediating the nuclear import of
recombinant NP [29,30]. For NLS2, residue 214 on influ-
enza A NP is probably one of the most important residues
as an arginine or lysine is found in that position in influ-
enza A, B, and C.
The exact length of NLS2 also remains to be determined.
Previous studies had implicated that NLS2 was a bipartite
NLS of 19 amino acids long, spanning residues 198 to 216
[31]. However, recent structural data has questioned that
this NLS functions as a bipartite classical NLS since the
crystal structure of NP showed that the two clusters of
basic residues of the bipartite NLS2 on NP were located
too close together in space to be functional as a bipartite
NLS [5]. Even though NLS2 may not be a bipartite NLS,
the relevance of residues 213, 214, and 216 on NP in
mediating the nuclear import of recombinant NP appears
to be significant [31]. However, which other residues in
NLS2 are important in mediating influenza nuclear
import remains to be determined.
Our studies here with influenza vRNPs also confirm find-
ings with recombinant NP that NLS1 is the stronger of the
two NLSs [29,31,37]. From the crystal structure of NP [5],
it is probably reasonable to assume that NLS1, being an
N-terminal sequence near the edge of NP, may be more
accessible to the binding of cytosolic nuclear import fac-
tors than NLS2. However, having both NLS1 and NLS2 as
functional NLSs on influenza vRNPs could serve a vital
purpose to the virus. If, in the event that the N-terminal
NLS1 is inadvertently cleaved off by any proteases in its
host cell, the vRNP may still have an extra NLS (NLS2) to
mediate its nuclear import. Nonetheless, it appears that
with so many copies of NP, it does seem to be a redundant
function. However, it is not clear how many of these NLSs
are exposed when NP oligomerizes and associates with
the vRNA. Therefore, further studies at understanding the
kinetics, cellular targets, conformational states, and role in
viral replication of NLS1 and NLS2 will be required to
bring further light to their roles in influenza cellular traf-
ficking and replication.
Previous work by other groups have concentrated mainly
on the nuclear import of recombinant NP [5,27-31,37].
These studies have provided a better understanding of the
role of the various NLSs on NP in the nuclear import of
newly-synthesized NP, which occurs after the initial
nuclear import of the entire vRNP complex and the subse-
quent synthesis of new NP in the cytoplasm [12,14]. To
study the nuclear import of influenza vRNPs, O'Neil et al.
(1995) [27], and more recently Cros et al. (2005) [26],
formed in vitro-assembled NP-RNA complexes by incubat-
ing recombinant NP with in vitro-synthesized influenza
vRNA. To study the nuclear import of the influenza
genome, however, vRNPs purified from influenza virions
would likely be the preferred substrates over in vitro-
formed vRNA-NP complexes. This is because the actual
assembly of NP into an oligomeric structure, and the
interactions of NP with the vRNA in actual influenza
infections, would likely result in structural differences
between  in vitro-formed RNA-NP complexes versus
virally-produced and assembled vRNPs. For example, cer-
tain NLSs may be exposed or hidden according to how NP
actually interacts with itself in the oligomer and how NP
interacts with the vRNA. In addition, NP molecules within
actual influenza vRNPs that are produced in mammalian
cells may have differences in their post-translational mod-
ifications compared to recombinant NP molecules pro-
duced in bacteria. Furthermore, any conformational
changes in the structure of the vRNPs after influenza
export from the cell, viral entry into a new cell, and during
or after their exit from endosomes are not taken into
account by in vitro-formed RNA-NP complexes. The meth-
odological differences in the preparation of vRNPs may
therefore explain the differences observed in studies using
in vitro-formed RNP and our results reported here using
naturally-occurring, influenza-derived vRNP complexes.
For example, Cros et al. [27] found that disruption of
NLS2 on NP has no effect on the nuclear accumulation of
in vitro-formed vRNA-NP complexes, while we showed
here that interfering with NLS2 on NP diminished the
nuclear import capability of influenza-purified vRNPs
(Figs. 4 and 5). Likewise, Ozawa et al. [37] found that
NLS2, but not NLS1, deletion mutants of NP were unable
to target effectively to nucleolar regions, while we showed
here that nucleolar localization still occurred whether
NLS1 or NLS2 on NP was inhibited.
Much work on understanding the nuclear import of the
influenza genome still remains. For example, the nuclear
accumulation sequence (NAS) within influenza-assem-
bled vRNP complexes is still a mystery. The NAS on NP
was originally found to mediate nuclear accumulation of
NP in Xenopus oocytes [45], but more recently has been
found to be a cytoplasmic retention signal in mammalian
cells [30,31,46]. It would therefore be useful to under-
stand in greater detail the role of the NAS and how its
function relates to that of NLS1 and NLS2. In addition, the
role of M1 in preventing nuclear import of vRNP is still
unclear [11,39]. For example, M1 may be acting indi-
rectly, where interaction of M1 with the vRNPs causes the
vRNPs to change their structural conformation [47] and
thus expose or hide certain NLSs. Alternatively, M1 may
be binding directly to the NLSs of vRNPs to inhibit their
nuclear import. The studies completed to date also raiseVirology Journal 2007, 4:49 http://www.virologyj.com/content/4/1/49
Page 9 of 12
(page number not for citation purposes)
the question as to under what conditions and in what con-
formational states of NP would NLS1 and NLS2 act to
mediate the nuclear import of vRNPs. Further unraveling
the answers to these questions may give us a more
detailed understanding of how the various NLSs on the
influenza vRNPs work together or independently to medi-
ate influenza A nuclear import.
Conclusion
In summary, we have showed in this study that inhibition
of either NLS1 or NLS2 on NP from influenza-derived
vRNP complexes significantly decreased the extent of
nuclear localization of the influenza genome. Further-
more, inhibiting both NLSs resulted in an additive effect,
causing an even greater decrease in vRNP nuclear accumu-
lation. This indicates that both NLS1 and NLS2 on NP
play a critical role in nuclear import by acting independ-
ently to mediate the nuclear import of incoming influenza
A vRNP complexes. The importance of our findings in the
design and development of novel influenza antiviral ther-
apeutics is critical, as both NLSs will likely require to be
inhibited to more completely abolish influenza nuclear
import and thus viral replication.
Methods
Purification of influenza vRNP complexes
Virally-derived influenza vRNPs were purified according
to Kemler et al. [38] with minor modifications: 1 ml of the
H3N2 X-31 A/AICHI/68 strain of influenza A (Charles
River Laboratories, Wilmington, MA) at 2 mg ml-1 was
washed in 30 mM Tris, pH 7.5, 20 mM MES, and 150 mM
NaCl, and then centrifuged for 10 minutes, 4°C, at
109,000 × g using a TLA-120.2 rotor in an Optima Max-E
centrifuge (Beckman Coulter, Fullerton, CA). The pellet
was resuspended in 0.5 ml disruption buffer (100 mM
MES, pH 5.5, 100 mM KCl, 5 mM MgCl2, 5% glycerol, 50
mM octylglucoside (Sigma, St. Louis, MO), 10 mg ml-1
lysolecithin (Sigma), and 1.5 mM dithiothreitol (Sigma)).
After shaking and vortexing at 31°C, this sample was
loaded onto a glycerol gradient containing 1 ml 70% glyc-
erol, 0.75 ml 50% glycerol, 0.375 ml 40% glycerol, and
1.8 ml 33% glycerol in buffer containing 50 mM MES, pH
5.5, and 150 mM NaCl. Centrifugation was performed for
3.75 hours at 4°C in an MLS-50 rotor at 217 000 × g. Frac-
tions were analyzed on a reducing SDS gel containing
10% polyacrylamide. Gels were stained in 0.025%
Coomassie brilliant blue G-250 (Sigma). Peak fractions
containing the vRNPs were pooled, washed in Ultrapure
DEPC-treated water (Invitrogen, Carlsbad, CA) by ultra-
centrifugation in a TLA-120.2 rotor at 157,000 × g for 4.5
hours at 4°C, and concentrated by resuspending the pel-
lets in DEPC-treated water. The A280 of the concentrated
vRNP was measured, and samples were aliquoted and fro-
zen at -80°C. As NP is the major component present in
the pooled fractions, an estimate of the molarity of NP
was calculated using its extinction coefficient of 55,350 M-
1 cm-1 (as determined via ProtParam [48]), to calculate the
amount of peptides or antibodies required for the compe-
tition and inhibition studies.
Biotinylation of influenza vRNP complexes
The 5' EndTag Nucleic Acid Labeling kit (Vector Laborato-
ries, Burlingame, CA) was used to covalently attach a reac-
tive thiophosphate group to the 5' end of the vRNA in the
vRNP complex: The 5' phosphate from the vRNA was
removed with alkaline phosphatase at 37°C for 30 min-
utes, followed by transferal of the thiophosphate from
ATPγS to the vRNA 5' end with T4 polynucleotide kinase
at 37°C for 30 minutes. Biotin-maleimide (Sigma), which
binds to the sulfur on the thiophosphate, was then incu-
bated with the thiophosphorylated vRNP complex at
65°C for 30 minutes.
Urea gel electrophoresis and Northern blotting of 
biotinylated vRNA
Purified influenza vRNPs were diluted in loading dye con-
taining TBE buffer (45 mM Tris, pH 8, 45 mM boric acid,
1 mM EDTA), 0.1% SDS, 0.08 mg ml-1 yeast RNA (Roche
Applied Science, Basel, Switzerland) to scavenge any
RNases, glycerol, and the tracking dyes bromophenol blue
and xylene cyanol. The sample was heated at 93°C for 3
minutes, and then applied to a urea polyacrylamide gel
(8.3 M urea and 6% polyacrylamide in TBE buffer). The
vRNA was visualized by staining for 30 minutes at room
temperature with the SYBR Safe dye (Invitrogen). RNA
molecular weight standards (Sigma) were used to deter-
mine the relative mobility of the vRNA.
For Northern blotting, the unstained gel was transferred
onto nitrocellulose, and blotted with the UltraSNAP
Detection Kit (Vector Laboratories). This kit contained
alkaline phosphatase-streptavidin to allow for the visuali-
zation of biotinylated influenza vRNA.
Negative staining and transmission electron microscopy
Biotinylated vRNPs were incubated with streptavidin-gold
(10-nm diameter) (Ted Pella, Redding, CA) overnight at
4°C. The sample was then absorbed onto 2% parlodion/
carbon-coated electron microscopy grids for 5 minutes,
washed with buffer containing 20 mM Tris, pH 7.4, and
120 mM KCl, and negatively stained with 1% uranyl ace-
tate. Grids were visualized in a Hitachi H7600 transmis-
sion electron microscope (Hitachi High Technologies
America, Schaumburg, IL).
Conjugation of nuclear import substrates with 
fluorophores
As a control, bovine serum albumin (BSA) was covalently
attached to a peptide (CGGGPKKKRKVED) containing
the NLS of the simian virus 40 large T antigen at a ratio ofVirology Journal 2007, 4:49 http://www.virologyj.com/content/4/1/49
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5:1 of NLS:BSA (conjugated by Sigma Genosys). The NLS-
BSA was then conjugated to the Cy3 fluorophore (Amer-
sham Biosciences, Piscataway, NJ), via incubation with
0.1 M sodium bicarbonate, pH 9.3, for 1 hour at room
temperature. Biotinylated vRNP was conjugated to
streptavidin-fluorescein (Vector laboratories) by incuba-
tion with streptavidin-fluorescein for one hour on ice.
Nuclear import assay in digitonin-permeabilized HeLa 
cells
Adherent HeLa cells (American Type Culture Collection)
were grown in a 37°C incubator containing 5% CO2 in
Dulbecco's modified Eagle medium (HyClone, Logan,
UT) supplemented with 9% fetal bovine serum (Sigma),
penicillin-streptomycin (Sigma), 1 mM sodium pyruvate
(Cellgro, Herndon, VA), and 2 mM L-glutamine (Cellgro).
The nuclear import assay is based on that of Adam et al.
[40]. Briefly, the HeLa cells were seeded onto glass cover
slips such that they were 60–70% confluent the next day.
The HeLa cells were then rinsed with import buffer (20
mM HEPES, pH 7.4, 110 mM potassium acetate, 1 mM
EGTA, 5 mM sodium acetate, 2 mM magnesium acetate,
and 2 mM dithiothreitol), and permeabilized with 20 μg
ml-1 digitonin in import buffer at room temperature for 5
minutes. After further washes with import buffer, the
cover slips containing digitonin-permeabilized cells were
inverted and incubated with the import mixture contain-
ing Cy3-labeled cNLS-BSA or fluorescein-labeled vRNP
for 45 minutes at 37°C in the presence or absence of exog-
enous 20% cytosol (rabbit reticulocyte lysate, Promega
(Madison, WI)) and an energy-regenerating system (0.4
mM ATP, 0.45 mM GTP, 4.5 mM phosphocreatine and 18
U ml-1 phosphocreatine kinase (all from Sigma)). To pre-
vent nonspecific binding, 1.6 mg ml-1 BSA (Sigma) was
added. Protease inhibitors (chymostatin, leupeptin,
antipain, and pepstatin, all from Sigma) at 10 μg ml-1 were
also included. The cells were then washed, fixed with 4%
paraformaldehyde in import buffer, and mounted with
the Prolong Gold antifade reagent containing DAPI (Inv-
itrogen). As a control, 70 kDa dextran Texas Red (Invitro-
gen) was applied to ensure that permeabilization of the
plasma membrane, but not the nuclear membrane, had
occurred [49]. In some experiments 100 μg/ml of the
monoclonal antibody MAb414 (Covance), which recog-
nizes proteins of the NPC and block nuclear import, was
used.
Peptide competition studies
Peptides bearing the sequences of NLS1
(1MASQGTKRSYEQM13) and NLS2
(198KRGINDRNFWRGENGRKTR216) on influenza A NP
were synthesized by Pacific Immunology (San Diego,
CA). As a control peptide, a mutated version of a cNLS-
bearing peptide (CYTPPKTKRKV), which contains a thre-
onine (underlined) at position 7 instead of a lysine and
thereby does not support nuclear import [42], was used
(synthesized by Sigma Genosys). For the peptide compe-
tition experiments, a 500-fold molar excess of the NLS1 or
NLS2 peptides (500:1 of peptides: NP) was used in the
nuclear import assay. For these experiments, the peptides
were pre-incubated with exogenous cytosol for one hour
at 4°C prior to addition of fluorescein-vRNP and initia-
tion of the import assay. To maintain constant peptide
concentrations, a 1000-fold molar excess of combined
peptides was used for each sample. The control peptide
was therefore used where only a single NLS1 or NLS2 pep-
tide was added. (For example, a 1000-fold molar excess of
control peptide only was used for the control sample, and
a 500-fold excess of control peptide + 500-fold excess of
NLS1 peptide was used for the NLS1 peptide sample).
Experiments were also performed with an excess of just
the NLS1 or NLS2 peptides without containing control
peptide.
Antibody inhibition studies
Polyclonal antibodies to the above peptides mimicking
NLS1 or NLS2 on NP were produced and affinity purified
by Pacific Immunology. The specificity of these antibodies
was checked by both dot blots and Western blots. Both
antibodies specifically reacted with their correspondent
peptide and with purified vRNPs.
For the nuclear import studies, each antibody was used at
an eight-fold molar excess (8:1 of antibodies:NP) in the
nuclear import assay. Anti-BSA (Sigma) was used as a con-
trol antibody. Antibodies were initially incubated with the
fluorescein-vRNP for one hour at 4°C prior to initiation
of the import assay. To maintain constant antibody con-
centrations, a 16-fold molar excess of combined antibod-
ies was used for each sample. The control antibody was
therefore used where only a single antibody was added.
Experiments were also performed with just the anti-NLS1
or the anti-NLS2 antibodies without containing control
antibody.
Fluorescence microscopy
Conventional fluorescence microscopy was performed on
a Zeiss Axioplan 2 (Carl Zeiss, Oberkochen, Germany).
Confocal laser scanning microscopy was performed on a
Zeiss Pascal LSM 5 (Carl Zeiss).
Quantification of nuclear import
To quantify the nuclear import of the fluorescently-
labeled cargo, the ratio of the nuclear-to-cytoplasmic flu-
orescence signal was determined. For this purpose, the
intensity of the nuclear and cytoplasmic fluorescence was
measured using ImageJ (National Institutes of Health,
Bethesda, MD) according to Schedlich et al. [49]. Cells
imaged under conventional fluorescence microscopy were
used for quantitation because it more accurately reflectedVirology Journal 2007, 4:49 http://www.virologyj.com/content/4/1/49
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the total amount of fluorescence in the nucleus and the
cytoplasm, as opposed to confocal microscopy, which
only imaged the cells at one plane. To quantify the nuclear
import, the background was first subtracted with ImageJ.
Next the mean intensity of a defined area (20 pixels by 20
pixels) in the nucleus was measured and divided by the
mean intensity of the same amount of area in the cyto-
plasm from the same cell. The area of the nucleus was cho-
sen as close to the centre of the nucleus as possible,
usually covering about 80% of the nucleus stained. The
cytoplasmic area was chosen to be representative of the
fluorescence intensity of the entire cytoplasm of the cell,
usually covering about 40% of the total cytoplasm. The
staining of the nuclear envelope was not included in the
quantification. As photographs were imaged at intensities
below saturation, there should not have been any prob-
lems with oversaturation of a certain area of the cell.
Between 100–110 cells were quantified for each condi-
tion.
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